6533b859fe1ef96bd12b7991
RESEARCH PRODUCT
Prevalence of Autoantibodies to the p53 Protein in Autoimmune Hepatitis
Varda RotterJan-philip ModrowSonja BambergerIrun R. CohenJohannes HerkelAnsgar W. LohseStephan Kanzlersubject
MaleHepatitisAutoimmune diseasebusiness.industryImmunologyAutoantibodyAutoimmune hepatitisHepatitis CMiddle AgedHepatitis Bmedicine.diseasedigestive system diseasesHepatitis AutoimmunePrimary biliary cirrhosisimmune system diseasesImmunologymedicineHumansImmunology and AllergyFemaleTumor Suppressor Protein p53businessViral hepatitisAutoantibodiesdescription
The target antigens of anti-nuclear autoantibodies in autoimmune hepatitis (AIH) are poorly characterised. Since antibodies to the p53 nuclear protein have been reported in various autoimmune diseases, we have assessed the prevalence of these antibodies in patients with AIH (n = 45), primary biliary cirrhosis (n = 60), hepatitis B (n = 22), hepatitis C (n = 55), and in a control group of subjects with various non-liver diseases (n = 56). A significant proportion of patients with AIH (31%) had elevated levels of autoantibodies to the p53 protein. In contrast, the prevalence of these antibodies in primary biliary cirrhosis (8%) and viral hepatitis (6%) was similar to that in the control group (4%). The clinical features of the anti-p53 seropositive AIH patients were similar to those of the seronegative ones. Thus, the prevalence of p53 autoantibodies in AIH is higher than in other forms of chronic hepatitis, and may be useful in differential diagnosis.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-05-27 | Autoimmunity |